Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Regina Esser"'
Autor:
Shukui Qin, Tianshu Liu, Jianming Xu, Qi Li, Ying Cheng, Aimar Zhang, Regina Esser, Helena Chang, Jin Li
Publikováno v:
Future Oncology.
Aim: To examine the impact of tumor sidedness on clinical outcomes in Chinese patients with metastatic colorectal cancer treated with folinic acid/fluorouracil/oxaliplatin (FOLFOX-4) ± cetuximab in the TAILOR trial. Patients & methods: Clinical data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beb357e3840d9b34619e95d200d3b562
https://doi.org/10.2217/fon-2022-1068
https://doi.org/10.2217/fon-2022-1068
Autor:
Stefan Kasper, Caroline Foch, Regina Esser, Francois-Xavier Lamy, Aimar Zhang, Ann-Lii Cheng, Magali Rouyer, Thomas Brodowicz, Christoph Zielinski
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af387d5388e8600e92099de8020e488
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85144553237
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85144553237
Autor:
Peter Gibbs, Timothy J. Price, Ann-Lii Cheng, Brigette B.Y. Ma, Robert Lim, Lin Shen, Regina Esser, W. Chen
Publikováno v:
Asia-Pacific Journal of Clinical Oncology
Aim The open‐label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wild‐type (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of first‐line, every‐2‐weeks cetuximab plus investigator's choic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2402940d5690ced13210375b45c1d85e
https://doi.org/10.1111/ajco.13154
https://doi.org/10.1111/ajco.13154
Autor:
Christoph C. Zielinski, W. Chen, Stefan Kasper, Caroline Foch, Francois-Xavier Lamy, Regina Esser, Diethelm Messinger, Vivien Rothe, Magali Rouyer, Thomas Brodowicz, Ann-Lii Cheng
Aim This study assessed whether cetuximab 500 mg/m2 administered every 2 weeks (Q2W), when combined with chemotherapy as a first-line (1L) treatment, was noninferior to the approved dose (400 mg/m2 followed by 250 mg/m2 once weekly [Q1W]) for overall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3680e0bbc373927d91757ff577d3e4b
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85098158489
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85098158489
Autor:
Michael Moran, Jan de Boer, Sebastian Stintzing, Jean Bourhis, Satu Salmio, Marc Van den Eynde, Andreas Schroeder, Regina Esser, Fortunato Ciardiello, Alexander Stein, Gregory Pennock, Kathryn A. Gold, Jürgen C. Becker
Publikováno v:
Cancer treatment reviews, Vol. 97, no.1, p. 102172 (2021)
Cancer treatment reviews, Vol. 97, p. 102172 [1-9] (2021)
Cancer treatment reviews, Vol. 97, p. 102172 [1-9] (2021)
Treatment outcomes have improved with the advent of immune checkpoint inhibitors and small molecule inhibitors. However, many patients do not respond with single agents. Consequently, ongoing research is focused on the use of combination therapies to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed7f15fb20af27571eb8555e9b877bf
https://www.ncbi.nlm.nih.gov/pubmed/33989949
https://www.ncbi.nlm.nih.gov/pubmed/33989949
Autor:
Regina Esser-Palm
Dörtes Yoga-Haus an einem Montagabend im Frühsommer nach dem ersten Corona-Lockdown: Das Yogastudio ist wieder geöffnet, die elf Yoginis dürfen wieder gemeinsam Yoga mit ihrer Lehrerin Dörte praktizieren. Der zweite Teil der „Yoginis“-Romane
Autor:
Regina Esser-Palm
Ein Figurenroman in 13 Pranayamas Dörtes Yoga-Haus am frühen Montagabend: Die elf Yoginis dürfen sich nach Überwindung der pandemischen Krisenzeiten wieder ohne Einschränkung treffen und voller Freude Yoga praktizieren. Der dritte und letzte Tei
Autor:
J. Tabernero, Christophe Borg, E. Liu, L. Limon, C. López-López, Gene Grant Finley, S. Salim, Christophe Tournigand, John H. Strickler, Antonio Cubillo, Regina Esser, T. S. Bekaii-Saab, M.J. Safont Aguilera, Frank Beier, Svenja Adrian, Rocio Garcia-Carbonero, Nuria Rodríguez-Salas, Kanwal Pratap Singh Raghav
Publikováno v:
Annals of Oncology. 32:S136-S137
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01c302460e548cdfe21d0064bd2926e2
https://doi.org/10.1016/j.annonc.2021.05.166
https://doi.org/10.1016/j.annonc.2021.05.166
Autor:
Howard A. Burris, Gary Middleton, Alberto Sobrero, Cathy Eng, Wen-Feng Chen, Werner Scheithauer, Heinz-Josef Lenz, Johannes Nippgen, Regina Esser
Publikováno v:
The Oncologist
Background The multicenter, open‐label, randomized, phase III EPIC study (EMR 062202‐025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor–detectable metastatic colorectal cancer (mCRC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1180f63e4586c41fade48092f2cf4907
https://pubmed.ncbi.nlm.nih.gov/33191588
https://pubmed.ncbi.nlm.nih.gov/33191588
Autor:
Thibault Mazard, Chiara Cremolini, Erika Martinelli, Gunnar Folprecht, Akihito Tsuji, Regina Esser, Dominik Paul Modest, Alfredo Falcone
Publikováno v:
Cancer Treatment Reviews. 102:102301
Doublet or triplet chemotherapy regimens in combination with anti–epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mAb), such as cetuximab or panitumumab, or the anti–vascular endothelial growth factor mAb bevacizumab, are the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a331d1bca9ca0f8edee28a81597307a9
https://doi.org/10.1016/j.ctrv.2021.102301
https://doi.org/10.1016/j.ctrv.2021.102301